Collaborative Fund Advisors LLC Invests $2.05 Million in BioMarin Pharmaceutical Inc. $BMRN

Posted by George Bondi on Jul 6th, 2026

Collaborative Fund Advisors LLC bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) during the first quarter, HoldingsChannel reports. The firm bought 36,312 shares of the biotechnology company’s stock, valued at approximately $2,051,000. BioMarin Pharmaceutical accounts for approximately 1.3% of Collaborative Fund Advisors LLC’s investment portfolio, making the stock its 21st largest position.

Several other large investors have also modified their holdings of BMRN. Norges Bank bought a new stake in BioMarin Pharmaceutical in the fourth quarter valued at about $447,572,000. Vestal Point Capital LP lifted its holdings in BioMarin Pharmaceutical by 261.4% during the 4th quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock worth $178,290,000 after buying an additional 2,170,000 shares during the last quarter. Capital Research Global Investors lifted its holdings in BioMarin Pharmaceutical by 547.5% during the 3rd quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock worth $137,436,000 after buying an additional 2,145,717 shares during the last quarter. Viking Global Investors LP grew its position in shares of BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after acquiring an additional 1,488,552 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of BioMarin Pharmaceutical by 48.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company’s stock worth $197,405,000 after acquiring an additional 1,076,568 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

Insider Transactions at BioMarin Pharmaceutical

In related news, EVP Gregory R. Friberg sold 3,281 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total transaction of $176,681.85. Following the completion of the transaction, the executive vice president directly owned 51,818 shares in the company, valued at $2,790,399.30. This represents a 5.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

BMRN has been the topic of several research reports. Sanford C. Bernstein dropped their price target on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Morgan Stanley decreased their price objective on shares of BioMarin Pharmaceutical from $120.00 to $119.00 and set an “overweight” rating for the company in a report on Tuesday, May 5th. Truist Financial upgraded shares of BioMarin Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. Wolfe Research reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Monday, March 16th. Finally, Canaccord Genuity Group reduced their price target on shares of BioMarin Pharmaceutical from $116.00 to $111.00 and set a “buy” rating on the stock in a research report on Friday, May 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $88.67.

Read Our Latest Report on BMRN

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock opened at $58.99 on Monday. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23. The business’s 50 day simple moving average is $54.80 and its 200-day simple moving average is $56.71. The stock has a market capitalization of $11.40 billion, a price-to-earnings ratio of 43.06, a PEG ratio of 0.45 and a beta of 0.24. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $66.28.

About BioMarin Pharmaceutical

(Free Report)

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.